SEER INC (SEER)       6.12  -0.34 (-5.26%)

6.12  -0.34 (-5.26%)

US81578P1066 - Common Stock


Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to SEER. SEER was compared to 65 industry peers in the Life Sciences Tools & Services industry. While SEER has a great health rating, but there are worries on its profitability. While showing a medium growth rate, SEER is valued expensive at the moment.




Profitability

Profitability Rating

1

SEER has a Return On Assets of -18.03%. This is comparable to the industry average of -16.45%.
The profitability ratios for SEER are negative, so there is not much use analyzing them.

SEER's Profit Margin of -646.27% is worse than the rest of the industry. The industry average Profit Margin is -29.71%. 95% of the industry peers have a better Profit Margin.
SEER has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of SEER.
VS Industry

ROA (-18.03%) VS Industry: 45% outperformed.

-620.54
57.39

Profit Margin (-646.27%) VS Industry: 5% outperformed.

-91,548.81
383.95

Valuation

Valuation Rating

3

With a price book ratio of 0.84, SEER is valued rather cheaply.
When comparing the price book ratio of SEER to the average industry price book ratio of 2.41, SEER is valued rather cheaply. SEER is also cheaper than 83% of the companies listed in the same industry.
Compared to an average industry Enterprise Value to EBITDA ratio of 15.69, SEER is valued rather cheaply

The Price/Earnings Ratio is negative for SEER. In the last year negative earnings were reported.
Also next year SEER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (0.84) VS Industry: 83% outperformed.

51.99
0.27

Enterprise Value/ EBITDA (4.51) VS Industry: 68% outperformed.

813.17
0.09

Growth

Growth Rating

4

The Revenue has grown by 258.81% in the past year. This is a very strong growth!
Based on estimates for the next 5 years, SEER will show a very strong growth in Revenue. The Revenue will grow by 94.75% on average per year.

SEER shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.07%.
The Earnings Per Share is expected to decrease by -5.67% on average over the next 5 years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -5.07% -35.41% -22.17% -11.66% -5.67%
RevenueN/A N/A 258.81% 174.63% 142.42% 125.65% 94.75%

Health

Health Rating

8

A Current Ratio of 33.08 indicates that SEER has no problem at all paying its short term obligations.
SEER is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 4.86. SEER has a better rating than 98% of its industry peers.
SEER has a Quick Ratio of 32.65. This indicates that SEER is financially healthy and has no problem in meeting its short term obligations.
The Quick Ratio of SEER is much better than the industry average of 4.30. SEER has a better rating than 98% of its industry peers.

The Debt to Equity ratio of SEER is way better than the industry averages.
An Altman-Z score of 5.64 indicates that SEER is not in any danger for bankruptcy at the moment.
When comparing the Altman-Z score to an average industry score of 2.30, SEER is in better financial health than the average industry peer.
The Piotroski-F score of SEER is 3.00. This is a low score and indicates issues in the health and profitability of SEER.
VS Industry

Debt/Equity (0) VS Industry: 71% outperformed.

3.88
0.00

Quick Ratio (32.65) VS Industry: 98% outperformed.

0.23
40.60

Current Ratio (33.08) VS Industry: 98% outperformed.

0.23
40.60

Altman-Z (5.64) VS Industry: 72% outperformed.

-119.90
26.33

Dividend

Dividend Rating

0

No dividends for SEER!.

SEER Daily chart

SEER INC6.12

NASDAQ:SEER (11/28/2022, 12:45:09 PM)-0.34 (-5.26%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Life Sciences Tools & Services
Earnings (Last) 11-08 2022-11-08/amc Earnings (Next) 02-27 2023-02-27
Ins Owners 4.07% Inst Owners 69.98%
Market Cap 383.37M Analysts 76
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 27.47 P/B 0.84
EV/EBITDA 4.51
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -5.07% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -26.67%
EPS Next Y -35.41% EPS Next 2Y -22.17%
EPS Next 3Y -11.66% EPS Next 5Y -5.67%
Revenue growth 1Y 258.81% Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q 83.53%
Revenue Next Year 174.63% Revenue Next 2Y 142.42%
Revenue Next 3Y 125.65% Revenue Next 5Y 94.75%
Health
Current Ratio 33.08 Quick Ratio 32.65
Altman-Z 5.64 F-Score 3
Debt/Equity 0 WACC 9.79%
ROIC/WACC N/A
Profitability
ROA -18.03% ROE N/A
ROICexgc N/A ROIC N/A
PM -646.27% OM -660.46%
Asset Turnover 0.03

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA